The Zephyr EBV is the only device designed for emphysema that has a clinically-validated diagnostic tool, the Chartis System, which can identify likely responders in order to optimize patient outcomes.
The filing was based on Pulmonx's pivotal IDE trial, the LIBERATE Study, a randomized controlled trial that enrolled 190 patients with severe emphysema at 24 centers in the US and Europe. The trial endpoints at one year included measures of lung function, exercise tolerance, and quality of life.
Three previous randomized controlled trials of the Zephyr EBV (TRANSFORM, IMPACT and STELVIO) also show that the treatment improves breathing, exercise capacity, and quality of life, while demonstrating long-term safety, in emphysema patients with little or no collateral ventilation as assessed with the Chartis System.
Zephyr EBVs are tiny, minimally-invasive, one-way valves placed via a flexible bronchoscope in airways in the lungs to block diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions of the lung can function more efficiently, enabling better breathing and an improved quality of life for patients.
Zephyr EBVs are widely used Europe, Australia, Asia, and South America as a treatment for severe emphysema. Over the past 10 years, more than 50,000 Zephyr EBVs have been implanted globally in more than 12,000 patients.
Pulmonx is focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib